Prothena Corporation plc - Ordinary Shares (PRTA) News
Filter PRTA News Items
PRTA News Results
|Loading, please wait...|
PRTA News Highlights
- PRTA's 30 day story count now stands at 13.
- Over the past 26 days, the trend for PRTA's stories per day has been choppy and unclear. It has oscillated between 1 and 4.
- The most mentioned tickers in articles about PRTA are BEAT, AXSM and BMY.
Latest PRTA News From Around the Web
Below are the latest news stories about PROTHENA CORP PUBLIC LTD CO that investors may wish to consider to help them evaluate PRTA as an investment opportunity.
Build and maintain your watch list with the latest news and analysis of the market's top-rated growth stocks.
Breakthrough Alzheimer’s treatments that remove toxic proteins from the brain have revived interest in vaccines to treat the memory-robbing disease, potentially offering a cheaper, easy-to-administer option for millions of people, according to interviews with 10 scientists and company executives. Clinical trials are underway or completed for at least seven Alzheimer’s vaccines designed to harness the immune system to rid the brain of the disease-related proteins beta amyloid or tau, a review of the U.S. government’s ClinicalTrials.gov database found. The renewed interest in Alzheimer's vaccines follows a promising first attempt more than 20 years ago that was abandoned after 6% of study volunteers developed life-threatening brain inflammation known as meningoencephalitis.
Prothena (PRTA) makes good progress with its AD candidates. However, AD is a challenging space and the successful development of these candidates is crucial.
Biogen and Eisai scored key victories in the quest for an Alzheimer's cure. But the race is just getting started.
Prothena (PRTA) delivers earnings of 38 cents in the third quarter, driven by the license and option exercise fee paid by BMY.
Company sees net income of $21.9 million for Q3, receives $55 million payment from Bristol Myers Squibb
Prothena (PRTA) delivered earnings and revenue surprises of 246.15% and 63.68%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
DUBLIN, November 02, 2023--Prothena today reported financial results for the third quarter and first nine months of 2023 and provided business highlights
Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biogen stock tumbled Thursday — pulling Prothena stock down — on mixed test results for an updated version of its Alzheimer's treatment.